Low Molecular Weight Fucoidan Suppresses Ferroptosis in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) remains a chronic, progressive interstitial lung disease with high morbidity and mortality, and therapeutic options are extremely limited. Standard treatments, including pirfenidone and nidanib, provide only modest benefits and are often accompanied by significant side effects, with little impact on long-term survival. Recent epidemiological data indicate a rising global burden, projecting up to 1.8 million cases worldwide by 2025, underscoring the urgent need for novel, efficacious interventions (reference study). Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a key pathological mechanism in PF, mediating alveolar epithelial damage, excessive extracellular matrix deposition, and progressive fibrotic remodeling. Although prior studies suggest that low molecular weight fucoidan (LMWF)—a sulfated polysaccharide from Laminaria japonica—possesses antioxidant and anti-inflammatory properties, its direct effects on ferroptosis and the mechanistic underpinnings of its protective action in PF had not been elucidated. This study addresses the central question: Can LMWF mitigate pulmonary fibrosis progression by specifically inhibiting ferroptosis and preserving mitochondrial function in a validated mouse model?

Key Innovation from the Reference Study

The core innovation lies in demonstrating that LMWF, produced via free radical degradation of native fucoidan, directly inhibits ferroptosis in vivo and in vitro. This is mechanistically significant because ferroptosis links iron overload, lipid peroxidation, and mitochondrial dysfunction—key drivers of epithelial cell loss and fibrotic progression in PF. Unlike previous studies focusing primarily on LMWF's antioxidant effects, this work dissects the molecular and metabolic events connecting ferroptosis suppression to improved mitochondrial membrane potential, reduced apoptosis, and restoration of alveolar architecture. The use of non-targeted metabolomics further distinguishes this approach, revealing comprehensive metabolic shifts associated with ferroptosis and LMWF intervention.

Methods and Experimental Design Insights

Bleomycin-induced PF in mice served as the principal disease model, emulating clinical and histopathological features of human fibrotic lung disease. The experimental workflow included:

• Administration of bleomycin to induce PF, followed by treatment with LMWF and/or the ferroptosis inducer erastin.
• Histological evaluation using hematoxylin and eosin and Masson’s trichrome staining to assess tissue architecture and collagen deposition.
• Immunohistochemistry and ELISA for quantifying alpha smooth muscle actin, glutathione peroxidase 4 (GPX4), collagen, and transforming growth factor beta 1 (TGF-β1).
• Flow cytometry to measure reactive oxygen species (ROS) levels, apoptosis, and mitochondrial membrane potential in lung tissue cells.
• Non-targeted metabolomics via liquid chromatography–mass spectrometry, validated with authentic metabolite standards, to map metabolic alterations associated with ferroptosis.
• Prussian blue staining to detect iron accumulation in lung tissues.

A critical component of the design was the assessment of mitochondrial membrane potential and apoptosis in conjunction with metabolic and histological endpoints, providing a multi-layered perspective on cell fate and organ function.

Protocol Parameters

• PF induction: Bleomycin administration to establish robust fibrotic pathology in mouse lung tissue.
• LMWF treatment: Applied post-bleomycin, with or without erastin challenge, to determine dose- and pathway-specific effects.
• Mitochondrial membrane potential assay: Flow cytometric analysis using potential-sensitive fluorescent probes, enabling quantification of mitochondrial health in situ.
• Metabolomic profiling: Liquid chromatography–mass spectrometry for unbiased detection of ferroptosis-related metabolic perturbations.

Core Findings and Why They Matter

LMWF treatment yielded several mechanistically linked outcomes:

• Significant reduction in collagen deposition and restoration of alveolar structural integrity, hallmarks of attenuated fibrosis.
• Decreased levels of ROS and apoptosis in lung tissue, as measured by flow cytometry, implicating improved cellular resilience.
• Restoration of GPX4 expression and glutathione content, both central to ferroptosis regulation and antioxidant defense.
• Suppression of iron accumulation and lipid peroxidation, as evidenced by Prussian blue staining and metabolomics data.
• Crucially, mitochondrial membrane potential was preserved in LMWF-treated animals, indicating protection against mitochondrial dysfunction—a pivotal event in ferroptosis-mediated cell death (reference study).

Collectively, these findings establish a direct mechanistic link between LMWF administration, ferroptosis inhibition, and the maintenance of mitochondrial and cellular homeostasis in PF. By targeting a regulated cell death modality with clear metabolic and functional readouts, LMWF offers a promising therapeutic avenue distinct from current anti-fibrotic agents.

Comparison with Existing Internal Articles

A central methodological advance in this study is the use of mitochondrial membrane potential assays as a sensitive readout of ferroptosis and apoptosis in lung tissue. This approach is consistent with best practices described in recent internal articles, such as:

• JC-1 Enables Precision Mitochondrial Membrane Potential Assays, which highlights the utility of JC-1 dye for ratiometric, live-cell detection of mitochondrial integrity in models of pulmonary fibrosis and ferroptosis.
• JC-1: The Premier Fluorescent Probe for Mitochondrial Mem..., which provides detailed workflow recommendations for apoptosis detection and mitochondrial dysfunction research in diverse disease models.

These guides emphasize the importance of mitochondrial membrane potential as a biomarker of bioenergetic status and cell fate. The reference study’s integration of these assays within a comprehensive metabolic and histological framework advances the field by providing a robust, multi-parametric strategy for evaluating anti-fibrotic interventions.

Limitations and Transferability

While the study establishes a compelling mechanistic rationale for LMWF as a ferroptosis inhibitor in PF, several limitations warrant consideration:

• The findings are based on a bleomycin-induced mouse model, which, while widely used, may not fully capture the complexity of human PF progression or heterogeneity.
• Long-term safety, pharmacokinetics, and optimal dosing of LMWF in clinical populations remain unaddressed.
• Potential off-target effects and interactions with standard PF therapies have not been systematically evaluated.

Nevertheless, the core molecular readouts—especially those involving mitochondrial membrane potential and metabolic profiling—are broadly applicable to other models of ferroptosis-driven organ injury, supporting the generalizability of the mechanistic insights.

Research Support Resources

Researchers aiming to replicate or extend these findings will require sensitive and robust mitochondrial membrane potential assays. Fluorescent probes such as JC-1 (5,6-dichloro-2-[(E)-3-(5,6-dichloro-1,3-diethylbenzimidazol-3-ium-2-yl)prop-2-enylidene]-1,3-diethylbenzimidazole iodide) are widely regarded as gold standards for this purpose, enabling precise ratiometric detection of mitochondrial health and apoptosis in live cells. To support such workflows, JC-1 (SKU A3516) from APExBIO offers validated quality and consistency for mitochondrial membrane potential assay and apoptosis detection. For detailed experimental protocols and troubleshooting, researchers can also consult comprehensive internal guides, such as those referenced above.